feedback

Faculty

James W.M. Owens, Jr, MD, PhD

Adam Kelly, MD

Accredited by

American Academy of Neurology

Course Description

LEARNING OBJECTIVES:

- State the proportion of pediatric patients with demyelinating disease who were treated with at least one form of newer disease modifying therapy (DMT) prior to age 18 in this study
- Describe the incidence of known and new side effects in pediatric patients receiving DMT in this study compared to adults receiving similar therapeutic regimens
- Identify patient and disease-specific predictors associated with a higher likelihood of receiving a newer DMT option in patients with pediatric demyelinating disease in this study

Activity Details

Credit Types:CME
Credit Amount:0.75 Credits
Release Date:2018-Nov-06
Expiration Date:2021-Nov-06
Registration Required:Yes
Cost:$807/yr

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.